MOLECUBES NV

Come meet us at the World Molecular Imaging Society conference! We will be at booth 301 with Bruker, #PMOD, and Spectral Instruments Imaging until September 13th. Meet Nas, Ewout, Scott, Todd, Andrew, and Guillaume to learn more about how preclinical imaging can accelerate your research. They are ready to answer your questions, demonstrate the newest hardware and software, and discuss solutions for your research. #WMIC2024 #PreclinicalImaging Bruker BioSpin Bruker Preclinical Imaging

💡 Application in the spotlight!   In this study by Zhang et al. of the Department of Radiology, University of Chicago, nicotinic receptor membrane-permeant ligands were radiolabeled and evaluated by dynamic PET-CT, combined with kinetic modeling, to investigate how these ligands distribute in the brain, an important question in nicotine addiction.   By combining in vitro and in vivo imaging, the researchers mapped both brain-wide and subcellular distributions of nicotinic receptor ligands, which provided useful information on nicotine addiction.   The β-cube (PET) and X-cube (CT) were used to measure the binding kinetics of α4β2R ligands in vivo, using [18F]2-FA and [18F]Nifene for brain PET imaging in mice.   🔗 Link to the application can be found in the comments!   #PreclinicalImaging #PreclinicalResearch #SPECT

🇨🇦 MOLECUBES is headed to Montréal, Canada, for the World Molecular Imaging Society (WMIC) conference from September 9 to 13! Find us at booth #301 with Bruker, #PMOD, and Spectral Instruments Imaging imaging instruments. 👩🔬 Come meet Nas Imus M.S., Scott D. Ireland, Todd Sasser, and Andrew Van Praagh and learn more about how preclinical imaging can accelerate your research. Our experts will be ready to answer your questions, demonstrate the newest hardware and software, and discuss solutions for your research. 💡 Visit the website via the link below to know more! #WMIC24 #PreclinicalImaging Bruker BioSpin Bruker Preclinical Imaging

🔬 Cubes in Action Excited to share some of the innovative work our customers are doing with our CUBES!   This time, we're highlighting a study by Matthijs Sevenois from the Vrije Universiteit Brussel, Molecular Imaging and Therapy Research Group (MITH Brussel).   In preclinical quantitative MicroPET/CT imaging, activity meter read-out might pose a challenge to accurate scanner calibration. To obtain reproducible and reliable quantitative imaging, the performance of individual preclinical PET/CT systems (partial volume effect, spillover,…) should be validated for each used radionuclide and incorporated into routine quality control.   This study aimed to compare the quantitative performance of 68Ga and 64Cu in the MOLECUBES β -CUBE and X-CUBE via a NEMA NU 4 phantom and compare activity meter response with an HPGe detector equipped with ISOCS software. MicroPET/CT imaging of 64Cu performs superior to 68Ga due to the impact of the large positron range of Ga68. In general, phantom measurements are necessary to determine the optimal number of iterations and the assessment of the stability of Recovery coefficients for different activity concentrations.   🔍 Interested in more applications like this? Visit the Knowledge Center on our website to see more of our customers' work in the spotlight. 🔗 Link to the application center can be found in the comments.   #CubesInAction #PreclinicalImaging #PreclinicalResearch

💡Application in the spotlight!    In this study by Sankaranarayanan et al., Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, a theranostic approach was investigated in a TNBC xenograft mouse model by radiolabelling a close derivative of a PARPi Olaparib (termed PARPi-01) with the Auger emitters 123/125I.   The γ-cube (SPECT) and X-cube (CT) were used for longitudinal follow-up and evaluation of the biodistribution of [123I]PARPi-01 four h and 24h post-injection.   🔗 Link to the application can be found in the comments! #PreclinicalImaging #PreclinicalResearch #SPECT

🔬 Cubes in Action Excited to share some of the innovative work our customers are doing with our CUBES!   This time, we're highlighting a study by Katty Zeven from the Vrije Universiteit Brussel, Molecular Imaging and Therapy Research Group (MITH).   While Immune checkpoint therapy (ICT) has revolutionized cancer treatment, therapy resistance persists due to the dynamic tumor environment. ICT targeting next-generation immune checkpoints, such as TIGIT, are being explored. However, reliable noninvasive diagnostic tracers for whole-body PET imaging of these checkpoints are needed for patient stratification and therapy follow-up. Radiolabeled small antibody fragments, such as nanobodies (Nbs) and their engineered variants, emerge as promising candidates for such tracer development.   In this study, the β-CUBE (PET) has been used to image [18F] and [64Cu] radiotracers in nude mice bearing wild-type (WT) and human TIGIT-overexpressing TC-1 tumors in the flanks. First, they looked for which nanobody (Nb) had the best uptake in the tumor, which was Cu64-Nb. Then, instead of conjugating with a nanobody, they used a 'Minabody' derived from an anti-human TIGIT Nb to increase circulation time, thus making it suitable for later time points. Minabody is currently being evaluated for its potential as a therapeutic compound.   🔍 Interested in more applications like this? Visit the Knowledge Center on our website to see more of our customers' work in the spotlight. 🔗 Link to the application center can be found in the comments.   #CubesInAction #PreclinicalImaging #PreclinicalResearch

Meet us at the 3rd Targeted Radiopharmaceuticals Summit US 2024 #TRPUS2024 in San Diego! 🇺🇸 Come and meet Kim Braeckman, who will tell you all about the latest features of our #CUBES. Ready to learn more about how the CUBES can support and elevate your research? Kim will be walking around at the conference until August 1st. #PET #SPECT #CT #shiftingstandards #PreclinicalImaging

Recently, we held an extraordinary sales training event in our hometown, Ghent. Our global team of sales superheroes met for an intensive week of product training, live demonstrations, insightful discussions on industry trends, and collaborative workshops. Of course, we also enjoyed some well-deserved social activities in the beautiful and vibrant city of Ghent!   These events are essential to successful collaboration, as they further strengthen our relations and allow us to learn from our global team of colleagues.   A heartfelt thank you to all presenters and organizers, whose dedication and hard work made this training a resounding success!   #SalesTraining Bruker BioSpin Bruker Preclinical Imaging

🔬 Cubes in Action! We're thrilled to highlight some of the innovative work our customers are doing with our CUBES!   This time, we're highlighting a study by Velislava Zoteva from the Ghent University Department of Radiology.   Glioblastoma(GB) is the most common primary malignant brain tumor in adults. Theranostics focus on targeting mutations and alterations in molecular pathways associated with GB pathogenesis, with recent emphasis on the promising role of PSMA, which is expressed in the GB neovasculature. In this study, the β-CUBE (PET) was used to evaluate PSMA expression. Heterogenous PSMA expression was confirmed in the peritumoral zone of the GB using immunostaining for PSMA and [68Ga/18F]PSMA PET. These findings indicate the suitability of the F98 GB rat model for further exploring the application of PSMA-based imaging and therapy.   In addition, the β-CUBE (PET) was used to examine the maximum administrable activity of [177Lu]PSMA and the corresponding tumor uptake with kidney dosimetry based on [18F]PSMA PET. In order to avoid nephrotoxicity, the maximum administrable activity of [177Lu]PSMA is 54 MBq, corresponding to a maximum dose of approximately 1.12 Gy, locally delivered to the tumor. However, given histological confirmation of PSMA expression primarily in the peritumoral zone, the tumor dose is expected to be higher in that area. [177Lu]PSMA monotherapy may not result in favorable outcomes, so [177Lu]PSMA needs to be administered as adjuvant therapy. 🔍 Interested in more applications like this? Visit the Knowledge Center on our website to see more of our customers' work in the spotlight. 🔗 Link to the application center can be found in the comments.    #CubesInAction #PreclinicalImaging #PreclinicalResearch

📢 Webinar alert! Join us for an insightful webinar on Hypoxia in the Tumor Immune Microenvironment (TIME) on July 11th at 4 PM CEST.   Join Prof. M. Bhujwalla, from the Johns Hopkins Radiology at the Johns Hopkins Medicine, who will review in vivo (e.g. PET/MR) and cellular and molecular (e.g. MRI/NMR spectroscopy) preclinical studies that provide new insights into varied tumor profiles/types and the underlying interplay in PD-L1 status, hypoxia, and fibroblasts in the tumor microenvironment.   Don't miss out to learn more about these new insights that pave the way for improved tumor therapies.     🔗 Register now via the link below! #PreclinicalImaging #Hypoxia #Oncology Bruker BioSpin Bruker Preclinical Imaging